ANTWERPEN, BELGIUM, Mar 23, 2026 - (ACN Newswire via SeaPRwire.com) - This marks the 11th time the company has been recognized as a Leader. OMP believes this recognition underscores its consistent delivery of innovative solutions such as UnisonIQ and Unison Decision-Centric Planning. It reflects a market shift toward AI-driven supply chain planning, and the growing demand for platforms that unify strategy, execution, and intelligence in real time.Advancing intelligent planning for the most complex supply chain needsTrusted by Fortune 500 leaders such as AstraZeneca, BASF, Johnson & Johnson, and Procter & Gamble, OMP continues to advance supply chain planning through Unison Planning™, its proven end-to-end platform. Open, cloud-native, and AI-driven, the platform is built to meet the evolving demands of process and discrete global supply chains, including chemicals, consumer goods, life sciences, paper and packaging, tires and building products, and metals.Unison Planning™ incorporates UnisonIQ, OMP's AI orchestrator that unifies AI agents, assistants, and engines into one powerful framework. Designed for the agentic age of supply chain planning, UnisonIQ embeds continuous intelligence throughout the platform, giving organizations a foundation for proactive, autonomous decision-making grounded in deep industry expertise."Agentic AI is fundamentally reshaping how supply chains operate and compete," says Paul Vanvuchelen, Chief Executive Officer at OMP. "Organizations that embrace this shift will turn volatility into strategic advantage."Accelerating decision velocity for the entire supply chainOMP's Unison Decision‑Centric Planning elevates supply chain performance by uniting human expertise, advanced AI, real‑time intelligence, and rapid scenario evaluation to drive decision velocity and improve decision quality across the enterprise."With comprehensive supply chain intelligence and AI-powered anticipation, Unison Decision-Centric Planning enables organizations to gain earlier visibility into disruption, evaluate its impact, and prepare the next move with clarity and confidence," says Philip Vervloesem, Chief Commercial & Markets Officer at OMP.About the Gartner Magic QuadrantThe 2026 Gartner Magic Quadrant for Supply Chain Planning Solutions: Process Industries, released in March 2026, evaluates vendors based on their Ability to Execute and Completeness of Vision, helping global companies identify the right partners in a complex and fast-evolving market.We believe this recognition comes alongside OMP's strong performance in the 2026 Gartner Critical Capabilities for Supply Chain Planning Solutions Process Industries report, where it had been ranked in the highest two positions across all Use Cases. OMP also continues to receive strong customer ratings on Gartner Peer Insights™, reflecting positive feedback from enterprise users.For more information about OMP's position as a Leader in the Gartner Magic Quadrant and the future of supply chain planning, read the full report.Meet OMP at the Gartner Supply Chain Symposium/Xpo™OMP will participate in the 2026 Gartner Supply Chain Symposium/Xpo™, where customers will share practical insights on intelligent, decision-centric supply chains:Procter & Gamble will present key learnings from its collaboration with OMP at the Symposium/Xpo™ US, highlighting how integrated planning and end-to-end visibility drive measurable business impact.AstraZeneca will present its journey toward decision-centric autonomous planning at the Symposium/Xpo™ EMEA, highlighting how it is transforming processes and capabilities to achieve excellence.About OMPOMP helps companies facing complex planning challenges to excel, grow, and thrive by offering the best digitized supply chain planning solution on the market. Hundreds of customers in a wide range of industries - spanning consumer goods, life sciences, chemicals, metals, paper, plastics & packaging, tires and building products - benefit from using OMP's unique Unison Planning™.Gartner, Magic Quadrant for Supply Chain Planning Solutions, Pia Orup Lund, Joe Graham, Buse Aras, Jan Snoeckx, Eva Dawkins, Julia von Massow, 18 March 2026.Gartner, Critical Capabilities for Supply Chain Planning Solutions: Process Industries, Julia von Massow, Eva Dawkins, Jan Snoeckx, Buse Aras, Joe Graham, Pia Orup Lund, 18 March 2026.Gartner and Magic Quadrant are trademarks of Gartner, Inc., and/or its affiliates.Gartner does not endorse any company, vendor, product or service depicted in its publications, and does not advise technology users to select only those vendors with the highest ratings or other designation. Gartner publications consist of the opinions of Gartner's business and technology insights organization and should not be construed as statements of fact. Gartner disclaims all warranties, expressed or implied, with respect to this publication, including any warranties of merchantability or fitness for a particular purpose.Gartner Peer Insights content consists of the opinions of individual end users based on their own experiences, and should not be construed as statements of fact, nor do they represent the views of Gartner or its affiliates. Gartner does not endorse any vendor, product or service depicted in this content nor makes any warranties, expressed or implied, with respect to this content, about its accuracy or completeness, including any warranties of merchantability or fitness for a particular purpose.Solution and product inquiriesContact OMPMedia inquiriesKira Perdue (Carabiner)SOURCE: OMP Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

TAMPA, FLA., Mar 23, 2026 - (ACN Newswire via SeaPRwire.com) - Wellgistics Health, Inc. ("Wellgistics" or the "Company") (NASDAQ:WGRX) today announced that it has entered into a non-exclusive, non-binding Letter of Intent ("LOI") to evaluate a potential acquisition of Neuritek Therapeutics, a neuroscience-focused research organization.The proposed all stock transaction, if completed, is intended to enhance Wellgistics' existing revenue-generating healthcare platform by expanding capabilities adjacent to its core technology-enabled pharmacy distribution and services business. Through its integrated ecosystem spanning prescription fulfillment, wholesale distribution, and AI-driven patient access solutions, Wellgistics connects manufacturers, providers, and a nationwide network of independent pharmacies. The Company believes that adding a research-focused organization could strengthen alignment between drug development and commercialization, enabling earlier engagement with pharmaceutical partners, improving pipeline visibility, and supporting incremental revenue opportunities while enhancing long-term shareholder value through a more integrated and differentiated platform.The transaction remains subject to the completion of due diligence, negotiation and execution of definitive agreements, approval by the boards of directors of the respective parties, and other customary closing conditions. There can be no assurance that a definitive agreement will be entered into or that the proposed transaction will be consummated on the terms currently contemplated, or at all. The LOI is non-binding and does not obligate either party to complete the proposed transaction. The scope, structure, and terms of any potential transaction remain under evaluation and may change materially as a result of ongoing diligence and negotiations.The Company is also actively evaluating additional strategic opportunities across the healthcare and life science sectors as part of its broader growth strategy. These opportunities may include acquisitions, partnerships, or other strategic transactions. There can be no assurance that any such initiatives will result in completed transactions.About Wellgistics Health, IncWellgistics Health is a rapidly scaling, technology-driven healthcare platform positioned at the center of pharmaceutical distribution and patient access. The Company has built an integrated, high-performance ecosystem spanning wholesale distribution, prescription fulfillment, and AI-powered access solutions, directly connecting pharmaceutical manufacturers, healthcare providers, and a nationwide network of independent pharmacies.By combining infrastructure, data, and intelligent automation, Wellgistics is executing on a capital-efficient model designed to capture significant share in large and fragmented healthcare markets. The Company is focused on expanding high-margin revenue streams, deepening strategic manufacturer relationships, and driving operating leverage across its platform. With a differentiated end-to-end offering and disciplined execution, Wellgistics is positioned to accelerate growth, enhance earnings visibility, and deliver outsized long-term value for shareholders.About Neuritek Therapeutics Inc.Neuritek Therapeutics Inc. has developed a next-generation bio-mechanism based treatment, treating the root cause of Post-Traumatic Stress Disorder (PTSD). Neuritek's first to market treatment is an orally active inhibitor of fatty acid amide hydrolase type 1 (FAAH1), the enzyme responsible for metabolizing anandamide (AEA) and the first mechanisms-based treatment for PTSD. The company was founded by Doctor William Hapworth MD., a pioneer in clinical research and a practicing psychiatrist with over 30 years' experience.Learn more at www.neuritek.com or join the conversation at LinkedIn, neuritek-therapeutics-incForward-Looking StatementsThis press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other applicable federal securities laws. These forward-looking statements include, without limitation, statements regarding: the potential acquisition of Neuritek Therapeutics, Inc. ("Neuritek"), including the anticipated structure, valuation, timing, and likelihood of completion of any transaction; the preliminary and non-binding nature of the letter of intent; the potential strategic, operational, and financial benefits of any such transaction; the Company's ability to negotiate and enter into definitive agreements; the Company's ability to obtain any required financing; the integration of any acquired business; and the Company's broader growth strategy and future performance.Forward-looking statements may be identified by words such as "may," "could," "would," "should," "expect," "anticipate," "believe," "intend," "plan," "project," "estimate," "potential," "opportunity," "target," "forecast," "continue," "will," and similar expressions.These forward-looking statements are based on current expectations, assumptions, and estimates and are subject to significant risks and uncertainties, many of which are beyond the Company's control. Important factors that could cause actual results to differ materially include, but are not limited to: the risk that the parties do not enter into definitive agreements; the risk that the letter of intent is terminated or does not result in a completed transaction; uncertainties related to the preliminary nature of the proposed valuation and transaction terms, which may change materially; the risk that any required financing is not obtained on acceptable terms or at all; the risk that anticipated benefits of any transaction are not realized; risks associated with integrating a research-focused organization into the Company's existing business; risks related to the development, testing, regulatory approval, and commercialization of pharmaceutical or therapeutic products, including the possibility of unfavorable clinical results or delays; regulatory and compliance risks; and other risks and uncertainties described from time to time in the Company's filings with the U.S. Securities and Exchange Commission.Forward-looking statements speak only as of the date they are made, and undue reliance should not be placed on such statements. The Company undertakes no obligation to update or revise any forward-looking statements, except as required by applicable law.Wellgistics Media & Investor ContactMedia: media@wellgisticshealth.comInvestor Relations: IR@wellgisticshealth.comSOURCE: Wellgistics Health, Inc. Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

Key Results Highlights:- Revenue Growth: 8.6% increase to approximately HK$1,813.8 million- Net Profit Increase: 3.5% rise to HK$318.1 million, driven by operational efficiency- Final Dividend: Proposed final dividend of HK7.0 cents per share, bringing total dividend for 2025 to HK14.0 cents per share, a 16.7% surge from HK12.0 cents in 2024- Net Cash & Cash Equivalents: HK$782.7 million (HK$557.2 million as at 31st December 2024)Regulatory Milestones:- NMPA Approval: Multi-dose Diquafosol Sodium Eye Drops approved in July 2025; multi-dose Sodium Hyaluronate Eye Drops approved in January 2026 for registration and commercialisation in the PRC- BLA Acceptance: Bevacizumab ophthalmic injection BLA accepted by NMPA in August 2025, marking a crucial regulatory milestoneBusiness Developments:- Exclusive Distribution (Seefunge): Exclusive distribution of Seefunge's Emedastine Difumarate and Oxybuprocaine Hydrochloride Eye Drops in the PRC- Exclusive Distribution (Osteopore): Exclusive distribution of Osteopore’s innovative dental, orthodontic and maxillofacial products in the PRC, Hong Kong and Macau.- Collaboration with Airdoc: Joint operation of Artificial Intelligence-based retinal businesses in the PRC- Strategic Collaboration with Kenvue: Promotion and marketing of Kenvue's consumer health products (Rhinocort(R), Motrin(R), Tylenol(R)) in the PRC.- International Innovation Accelerator: Signed MOU with Suzhou Industrial Park to launch cross-border life sciences accelerator.- First Overseas Market Entry: Beifushu(R) introduced to Singapore via Special Access Route at Singapore National Eye Centre.Intellectual Property and Market Presence:- Robust IP Portfolio: 121 patent certificates or authorisation letters, comprising 91 invention patents, 15 utility model patents and 15 design patents.- Extensive Distribution Network: Products available in over 14,600 hospitals and medical providers, and approximately 2,600 pharmaceutical stores across the PRCAwards and Recognition:- 2025 Top 500 Manufacturing Companies in Guangdong Province: Recognises industrial scale and comprehensive competitiveness- National Manufacturing Champion Enterprise: Affirms leading position in specialized biopharmaceutical segment- 2025 "Golden Kunpeng" China Financial Value Ranking – Most Valuable Listed Company for Investment: Highlights capital market recognition of growth potential- Participation at Asia-Pacific Academy of Ophthalmology Congress 2026: Showcasing key ophthalmology products and pipeline assets, strengthening engagement with regional eye care professionals and institutions.HONG KONG, Mar 23, 2026 - (ACN Newswire via SeaPRwire.com) - Essex Bio-Technology Limited (“Essex” and its subsidiary the “Group”, Stock Code: 1061.HK), a leading biologic Group that develops, manufactures and commercialises genetically engineered therapeutic recombinant bovine basic fibroblast growth factor (“rb-bFGF”), today announced robust annual results for the year ended 31st December 2025, with revenue up 8.6% to HK$ 1,813.8 million and net profit up 3.5% YoY to HK$318.1 million. The Group achieved multiple regulatory milestones and expanded its product portfolio through strategic collaborations, and Beifushu’s landmark entry into Singapore. These achievements underscore Essex's commitment to innovation and operational excellence, driving sustained revenue and profit growth.Diversified Growth Fueled by Flagship BiologicsThe Group achieved a consolidated turnover of approximately HK$1,813.8 million, with an increase of 8.6% as compared to approximately HK$1,669.8 million in 2024. Correspondingly, the Group’s profit increased by 3.5% to approximately HK$318.1 million as compared to approximately HK$307.2 million in 2024.The Beifushu(R) series and Beifuji(R) series, the Group’s flagship products drove growth, contributing 83.5% of turnover.The ophthalmology segment (“Ophthalmology”) recorded a turnover of HK$835.0 million, grew 8.2% year-on-year, led by Beifushu(R) unit-dose eye drops and supported by its preservative free design and expanding application scenarios, which cover multiple areas such as dry eye treatment and post-operative recovery, and contributions from Beifushu(R) eye gel, (Iodized Lecithin Capsules) and a range of unit-dose eye drops (Tobramycin, Levofloxacin, Sodium Hyaluronate, Moxifloxacin Hydrochloride and Diquafosol Sodium Eye Drops).The surgical segment (“Surgical”) turnover rose 1.8% year-on-year to HK$895.9 million, leveraging Beifuji’s broad clinical applications across multiple medical departments and strong market presence. It is also supported by numerous clinical guidelines and expert consensus, thereby laying a solid foundation for future indication expansion and sustained growth. In addition, Group Carisolv(R) dental caries removal gel, PELNACTM collagen-based artificial dermis and SCALGENTM double-layered artificial dermis had further strengthened and contributed to the Surgical business.Notably, Healthcare and Partner Services delivered a total turnover of approximately HK$82.9 million for the year ended 31st December 2025, representing a significant increase of 350% as compared to 2024. The growth was primarily driven by Dr. YaDian oral care products, online and offline healthcare services and CMO/CDMO services.Strengthening Financial Position and Shareholder ReturnsThe Group maintains a healthy financial position, with cash and cash equivalents of approximately HK$782.7 million as of 31st December 2025. Bank borrowings stand at HK$325.6 million, with a manageable repayment schedule over 5 years period. The Group’s gearing ratio is at 30.9% (2024: 28.8%), indicating disciplined financial management and ample liquidity.The Board is pleased to propose a final dividend of HK7.0 cents per ordinary share. Together with the interim dividend of HK7.0 cents per ordinary share, the total dividend for 2025 reaches HK14.0 cents, representing a notable year-on-year increase of 16.7% from HK12.0 cents in 2024, demonstrating the Group’s ongoing commitment to delivering greater returns to its shareholders.Broad Portfolio and Robust Pipeline Fuel Sustained GrowthThe Group’s business comprises three core segments: Ophthalmology, Surgical (wound care and healing) and Healthcare and Partner Services segment, with the Group’s six (6) flagship commercialised biologics, collectively referred to as the “bFGF Series”, which are marketed and sold in the PRC. Three of the bFGF Series were approved by NMPA as Category I drugs, and five are listed on the National Drug List for Basic Medical Insurance, Work-Related Injury Insurance and Maternity Insurance in the PRC.In addition, the Group offers a portfolio of commercialised preservative-free unit-dose eye drops, including Tobramycin, Levofloxacin, Sodium Hyaluronate, Moxifloxacin Hydrochloride and Diquafosol Sodium Eye Drops. The Group further expanded its ophthalmology franchise by obtaining NMPA approvals for the registration and commercialisation of multi-dose Diquafosol Sodium Eye Drops in July 2025 and multi-dose Sodium Hyaluronate Eye Drops in January 2026. The new launches target the PRC’s growing dry eye treatment market, complementing the Group’s Beifushu(R) ophthalmic repair series.As for the Surgical segment, the Group’s Carisolv(R) dental caries removal gel, Portable Ultraviolet Phototherapy Devices, PELNACTM collagen-based artificial dermis, SCALGENTM double-layered artificial dermis and Osteopore’s bioresorbable implants (Osteomesh(R) and Osteoplug(R)), are complementing the Group’s Beifuji(R) wound healing series.Strategic R&D Investment to Capture Emerging Market OpportunitiesThe Group is committed to pragmatically investing in new products and technologies to strengthen its product and R&D pipeline, with a mission to develop groundbreaking therapeutics that address unmet clinical and commercial needs. In 2025, total R&D expenditures were approximately HK$177.2 million, representing 9.8% of the turnover, of which approximately HK$139.3 million were capitalised.During the year, the Group’s Medical Scar Repair Gel obtained NMPA registration approval as a Class II medical device, expanding the Group’s footprint in the fast-growing high-end wound care and medical aesthetics markets, unlocking new growth drivers for long-term success.The global phase 3 clinical project of bevacizumab ophthalmic injection (EB12-20145P) has successfully completed patient enrolment across the PRC, Australia, European Union countries and the United States, with the last patient last visit was completed. A Biologics License Application (BLA) was accepted by NMPA in the PRC in August 2025.To amplify the Group’s presence in the Asia ophthalmic community and accelerate the market launch of new products, the Group participated in the 2026 Asia-Pacific Academy of Ophthalmology (APAO) Congress. The event provided a premium platform to showcase ophthalmic solutions, engage with regional clinical experts and partners, and build momentum for the rollout of its innovative ophthalmic products, reinforcing its global brand influence.The Group holds a total of 121 patent certificates or authorisation letters, comprising 91 invention patents, 15 utility model patents and 15 design patents.The Group currently has multiple R&D sites located in Zhuhai (PRC), Boston (United States), London (United Kingdom) and Singapore. These sites support the Group’s efforts to develop new therapeutics and recruit global talent.To date, the Group has 18 R&D programmes ranging from pre-clinical to clinical stages, with several ophthalmology programs currently in the clinical stage, specifically Bevacizumab intravitreal injection, SkQ1 eye drops and Cyclosporine eye dropsBroadening Commercial Reach Through Market Expansion and PartnershipsAs of 31st December 2025, the Group maintains an extensive network of 47 regional sales offices in the PRC and a strategic base in Singapore to facilitate market access into Southeast Asian countries. With a vast distribution network, the Group’s products are prescribed in more than 14,600 hospitals and medical providers, coupled with approximately 2,600 pharmaceutical stores, covering major cities throughout the PRC.During the year under review, the Group achieved multiple landmark breakthroughs in the PRC and overseas market expansion, unlocking new multi-dimensional growth momentum. In the overseas market, the Group’s flagship product Beifushu(R) was successfully introduced to Singapore via the Special Access Route at the Singapore National Eye Centre, marking the product’s first commercial launch beyond the PRC, and establishing a solid foothold to support the Group’s future expansion into Southeast Asia and global markets.In the PRC market, the Group entered into two landmark strategic partnerships during the year: a collaboration with global consumer health leader Kenvue, under which the Group will leverage its extensive nationwide commercial network in the PRC to carry out promotion, medical education and marketing for Kenvue’s selected consumer health products including Rhinocort(R) (Budesonide Nasal Spray), Motrin(R) (Ibuprofen Suspension/Drops), and Tylenol(R) (Paracetamol Drops/Suspension); and an exclusive distribution agreement for Osteopore’s innovative dental, orthodontic and maxillofacial products in the PRC, Hong Kong and Macau, marking a strategic entry into the high-potential stomatology market. The partnerships broaden the Group’s healthcare business footprint, delivering strong synergies with its existing ophthalmology and regenerative medicine lines.To drive sustainable growth and expansion for its current and future products, the Group has been investing relentlessly in enhancing its competitiveness and broadening its reach by expanding the clinical indications for its commercialised products, increasing patient access in lower-tier cities across the PRC, developing complementary sales channels, and nurturing the healthtech e-platform to enhance patient access.The Group’s second factory at Zhuhai Hi-Tech Industrial Park, with a gross floor area of about 58,000 square meters for R&D, manufacturing, office and dormitory, is expected to complete in the period of 2026 -2027.Mr. Patrick Ngiam, Chairman of Essex, said “2025 was a standout year with Beifushu’s landmark entry into Singapore, driving robust growth through flagship products, innovation-focused R&D, and strategic partnerships. Essex remains committed to addressing unmet needs and driving long-term growth.We will proactively and systematically recalibrate operating and distribution costs to mitigate the negative impact on FY26 profit from the increase of VAT from 3% to 13% without disrupting our focus on Group development plans.”About EssexBio (1061.HK)EssexBio is a bio-pharmaceutical company that develops, manufactures, and commercialises genetically engineered therapeutic b-bFGF, with six commercialised biologics currently marketed in China. Additionally, the Company has a diverse portfolio of commercialised preservative-free unit-dose eye drops, Shilishun (Iodized Lecithin Capsules) and others, which are principally prescribed for wound healing and diseases in Ophthalmology and Dermatology. These products are marketed and sold through approximately 14,600 hospitals, supported by the Company’s 47 regional offices in China. Leveraging its in-house R&D platform in growth factor and antibody technology, EssexBio maintains a robust pipeline of projects in various clinical stages, covering a wide range of fields and indications. Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

Brisbane, Australia--(ACN Newswire via SeaPRwire.com - March 23, 2026) - Graphene Manufacturing Group Ltd (TSXV: GMG) (OTCQX: GMGMF) ("GMG" or the "Company") is pleased to announce that the Company has officially launched its European sales activity. During the week of March 9th, GMG held a kick off training workshop in London where it brought together its new team members from various locations in Europe and UK for technical product and sales training.The GMG European Sales team numbers more than 10 professional sales executives based in Europe and UK who focus on lead generation, inside sales and executive sales business development for GMG's G® Lubricant and THERMAL-XR® products.Figure 1: Members of the GMG European Sales TeamTo view an enhanced version of this graphic, please visit:https://images.newsfilecorp.com/files/8082/289529_gmg_figure1.jpgSeparately, the Company is also pleased to announce that it has been informed that the G® Lubricant patent in Europe has been accepted to be granted for a period of 20 years.Craig Nicol, CEO & Managing Director of the Company, commented "Building a sales force in key areas of the world is one of GMG's key activities it is focused on right now and to get the European team set up and running so fast has been a great achievement."Jack Perkowski, Chairman and Non-Executive Director of the Company, commented: "I congratulate the Company on building the European Sales team and look forward to hearing of future success."About GMG:GMG is an Australian based clean-technology company which develops, makes and sells energy saving and energy storage solutions, enabled by graphene manufactured via in house production process. GMG uses its own proprietary production process to decompose natural gas (i.e. methane) into its natural elements, carbon (as graphene), hydrogen and some residual hydrocarbon gases. This process produces high quality, low cost, scalable, 'tuneable' and low/no contaminant graphene suitable for use in clean-technology and other applications.The Company's present focus is to de-risk and develop commercial scale-up capabilities, and secure market applications. In the energy savings segment, GMG has initially focused on graphene enhanced heating, ventilation and air conditioning ("HVAC-R") coating (or energy-saving coating) which is now being marketed into other applications including electronic heat sinks, industrial process plants and data centres. Another product GMG has developed is the graphene lubricant additive focused on saving liquid fuels initially for diesel engines.In the energy storage segment, GMG and the University of Queensland are working collaboratively with financial support from the Australian Government to progress R&D and commercialization of graphene aluminium-ion batteries ("G+AI Batteries"). GMG has also developed a graphene additive slurry that is aimed at improving the performance of lithium-ion batteries.GMG's 4 critical business objectives are:Produce Graphene and improve/scale cell production processesBuild Revenue from Energy Savings ProductsDevelop Next-Generation BatteryDevelop Supply Chain, Partners & Project Execution CapabilityFor further information please contact:Craig Nicol, Chief Executive Officer & Managing Director of the Company at craig.nicol@graphenemg.com, +61 415 445 223Leo Karabelas at Focus Communications Investor Relations, leo@fcir.ca, +1 647 689 6041Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accept responsibility for the adequacy or accuracy of this news release.Cautionary Note Regarding Forward-Looking StatementsThis news release includes certain statements and information that may constitute forward-looking information within the meaning of applicable Canadian and U.S. securities laws. Forward-looking statements relate to future events or future performance and reflect the expectations or beliefs of management of the Company regarding future events. Generally, forward-looking statements and information can be identified by the use of forward-looking terminology such as "intends", "believes" "expects" or "anticipates", or variations of such words and phrases or statements that certain actions, events or results "may", "could", "should", "would" or will "potentially" or "likely" occur. This information and these statements, referred to herein as "forward‐looking statements", are not historical facts, are made as of the date of this news release and include without limitation, the size, term and success of GMG's European sales team and the eventual granting of and successful enforceability of the Company's G® Lubricant patent.Such forward-looking statements are based on a number of assumptions of management, including the European sales team will perform and the Company's G® Lubricant patent will be patented successfully. Additionally, forward-looking information involves a variety of known and unknown risks, uncertainties and other factors which may cause the actual plans, intentions, activities, results, performance or achievements of GMG to be materially different from any future plans, intentions, activities, results, performance or achievements expressed or implied by such forward-looking statements. Such risks include, without limitation that the GMG European Sales team does not successfully drive sales for the Company and the Company's G® Lubricant patent is not patented and the risk factors set out under the heading "Risk Factors" in the Company's annual information form dated November 4, 2025 available for review on the Company's profile at www.sedarplus.ca.Although management of the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements or forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements and forward-looking information. Readers are cautioned that reliance on such information may not be appropriate for other purposes. The Company does not undertake to update any forward-looking statement, forward-looking information or financial out-look that are incorporated by reference herein, except in accordance with applicable securities laws.To view the source version of this press release, please visit https://www.newsfilecorp.com/release/289529 Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

SINGAPORE, Mar 23, 2026 - (ACN Newswire via SeaPRwire.com) - Travelling overseas is exciting, but foreign exchange (FX) fees can quietly add up and increase your overall trip expenses. Many Singaporeans are now exploring smarter ways to manage overseas spending, and a multi-currency debit card can help reduce unnecessary FX charges while shopping, dining, and booking activities abroad. Whether you are heading to Japan, Australia, Europe, or the US, understanding how FX fees work can help you stretch your Singapore dollars further. Even a 3% fee on a SGD 5,000 trip translates to SGD 150, which could easily cover a nice meal or attraction tickets.When spending overseas, banks typically apply a currency conversion spread and may also charge overseas transaction fees ranging between 2.5% and 3.5%. On top of that, dynamic currency conversion at merchants can add another 4-8% markup. These layered charges might not be obvious at checkout, but they can significantly increase your travel budget.With a bit of planning and the right payment tools, Singaporeans can minimise these costs and enjoy more transparent spending abroad.Understanding Where FX Fees Come FromBefore looking at solutions, it helps to understand how FX fees are structured. Most traditional credit and debit cards issued in Singapore apply a foreign transaction fee when you pay in a currency other than SGD. This fee usually combines the card network's conversion rate and an additional bank administrative charge.For example, if you spend the equivalent of SGD 1,000 in Bangkok or Seoul, a 3% fee adds around SGD 30 to your statement. Over a 10-day trip with shopping and dining expenses of SGD 4,000, total FX charges could reach SGD 120 or more. These amounts may seem small per transaction but can accumulate quickly across hotels, theme parks, transport passes, and shopping malls.How a Multi-Currency Debit Card Can HelpA multi-currency debit card allows users to hold and spend multiple foreign currencies directly from one account. Instead of converting SGD at the point of sale for every purchase, you can preload currencies such as USD, EUR, JPY, or AUD in advance. This setup can help reduce conversion fees and give you more control over exchange rates.For instance, if you are travelling to Japan and expect to spend the equivalent of SGD 3,000, you can convert SGD to JPY when rates are favourable before departure. If the exchange rate improves even by 1%, that difference could mean savings of around SGD 30 on your total spend.Many multi-currency debit cards also offer competitive interbank or near-interbank rates with low or zero foreign transaction fees. While terms vary by provider, this structure may result in lower overall costs compared to traditional cards. Additionally, you can track balances in different currencies via mobile apps, which helps you manage budgets more clearly during travel.Practical Ways Singaporeans Can Reduce FX ChargesBeyond choosing the right card, several practical habits can help minimise FX fees while shopping overseas.Pay in the local currency whenever possibleWhen a payment terminal offers the option to pay in SGD or the local currency, selecting the local currency can help you avoid dynamic currency conversion markups. Merchants may apply rates that are 4-8% higher than market rates when you choose SGD. On a SGD 2,000 shopping bill in Seoul, that difference could translate to an extra SGD 80 or more. Paying in the local currency often results in a more transparent rate from your bank or card provider.Plan large purchases in advanceIf you are considering buying luxury goods in Europe or electronics in Japan, estimating your total spend beforehand can help you prepare accordingly. Planning major purchases can also help you avoid last-minute conversions at less competitive airport rates.Avoid exchanging large sums at airportsAirport money changers often offer less competitive exchange rates compared to city money changers in Singapore or digital FX platforms. The difference might range from 1% to 3%. On SGD 2,000 exchanged at the airport, this gap could mean paying SGD 20 to SGD 60 more than necessary. Using a multi-currency debit card for most transactions can reduce the need to carry large amounts of cash.Monitor overseas ATM withdrawal feesWithdrawing cash overseas may involve both local ATM fees and your bank's overseas withdrawal charges. These combined costs can range between SGD 5 and SGD 15 per withdrawal, excluding FX spreads. Planning fewer, slightly larger withdrawals, or relying more on card payments, can help reduce repeated charges. Some multi-currency debit cards may offer more competitive ATM withdrawal terms, depending on the provider.Comparing Travel Spending OptionsCredit cards may offer travel rewards but often carry foreign transaction fees of around 3%. Using cash helps you to do away with card fees but requires you to exchange money upfront, sometimes at less competitive rates.A multi-currency debit card sits somewhere in between, combining digital convenience with potentially lower FX costs, while offering more flexibility. For frequent travellers visiting destinations like Malaysia, Thailand, Japan, Australia, or the US several times a year, this flexibility can make budgeting more predictable.Avoiding FX fees does not require complex strategies. Small adjustments in how you pay, when you convert currency, and which card you use can collectively reduce costs. While exchange rates fluctuate and fees vary across providers, informed decisions can help you minimise hidden charges and make the best of your overseas trips.Disclaimer: This article is for general information only and does not have any regard to the specific investment objectives, financial situation and particular needs of any specific person. The views expressed in this article are solely those of the author. This article shall not be regarded as an offer, recommendation, solicitation or advice. You may wish to consult your own professional advisers about this article, in particular, a financial professional before making financial decisions. Any past events, trends and/or performance referred to in this article may not necessarily be indicative of future events, trends or performance. This article is based on certain assumptions and reflects prevailing conditions as at the time of publication, which are subject to change at any time without notice. The author and publisher of this article as well as any other parties associated with this article make no representation or warranty of any kind, whether express, implied or statutory, in respect of this article and accept no liability or responsibility for the completeness or accuracy of this article or any error, inaccuracy or omission relating to this article and/or any consequence, injury, loss or damage howsoever suffered by any person relating to this article, in particular, arising from any reliance by any person on this article. Publishers or platforms may be compensated for access to third party websites.Contact Information:Name: Sonakshi MurzeEmail: Sonakshi.murze@iquanti.comJob Title: ManagerSOURCE: iQuanti Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com